RESUMO
Multi-target drug treatment has become popular as a substitute for traditional monotherapy. Monotherapy can lead to resistance and side effects. Multi-target drug discovery is gaining importance as data on bioactivity becomes more abundant. The design of multi-target drugs is expected to be an important development in the pharmaceutical industry in the near future. This review presents multi-target compounds against trypanosomatid parasites (Trypanosoma cruzi, T. brucei, and Leishmania sp.) and tuberculosis (Mycobacterium tuberculosis), which mainly affect populations in socioeconomically unfavorable conditions. The article analyzes the studies, including their chemical structures, viral strains, and molecular docking studies, when available. The objective of this review is to establish a foundation for designing new multi-target inhibitors for these diseases.
Assuntos
Antituberculosos , Simulação de Acoplamento Molecular , Mycobacterium tuberculosis , Mycobacterium tuberculosis/efeitos dos fármacos , Humanos , Antituberculosos/farmacologia , Antituberculosos/química , Antituberculosos/uso terapêutico , Trypanosoma cruzi/efeitos dos fármacos , Tuberculose/tratamento farmacológico , Tuberculose/microbiologia , Animais , Descoberta de Drogas , Leishmania/efeitos dos fármacos , Desenho de Fármacos , Tripanossomicidas/farmacologia , Tripanossomicidas/uso terapêutico , Tripanossomicidas/químicaRESUMO
BACKGROUND: Currently, the effectiveness of TACE, Lenvatinib, and PD-1/L1 inhibitors used alone or in combination has been thoroughly reported. However, the differences in effectiveness between these treatment protocols require further verification. To this end, this study employs a Bayesian network meta-analysis to compare the efficacy and safety of TACE, Lenvatinib, and PD-1/L1 inhibitors, whether administered by monotherapy or in combination, providing evidence-based medicine for the treatment of unresectable HCC. PURPOSE: This study employed a network meta-analysis to evaluate the efficacy and safety of trans-arterial chemoembolization (TACE), Programmed Cell Death Protein/Ligand 1 (PD-1/L1) inhibitors, and Lenvatinib in the treatment of advanced HCC. METHODS: Literature on the treatment of advanced HCC with TACE, PD-1/L1 inhibitors, and Lenvatinib was searched for in both Chinese and English databases, including PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library, CNKI, and Wanfang. Two researchers conducted independent screening and data extraction, and the meta-analysis was performed using R language with the gemtc package. RESULTS: After retrieval and screening, a total of 21 articles were included, involving 2052 participants and six treatment modalities: Lenvatinib (L), TACE (T), TACE + Lenvatinib (TL), Lenvatinib + PD-1/L1 inhibitors (LP), TACE + Lenvatinib + PD-1/L1 inhibitors (TLP), and TACE + PD-1/L1 inhibitors (TP). In terms of objective response rate (ORR), the TLP regimen provided the optimal effect. In predicting the best ORR, TLP had the highest (75.5%) probability. In terms of disease control rate (DCR), the TLP regimen showed the best effect. In predicting the best DCR, the TLP again offered the highest (76.1%) probability. In terms of overall survival (OS), the best outcome was observed in the TLP protocol. In predicting the best OS, the TLP holds the highest (86.00%) probability. Furthermore, the best outcome in progression-free survival (PFS) was found in the TLP regimen. In predicting the best PFS, the TLP still holds the highest (97.0%) result. CONCLUSION: The combination of TACE, Lenvatinib, and PD-1/L1 inhibitors appears to provide the maximum benefit for inoperable HCC patients.
Assuntos
Carcinoma Hepatocelular , Quimioembolização Terapêutica , Inibidores de Checkpoint Imunológico , Neoplasias Hepáticas , Compostos de Fenilureia , Quinolinas , Humanos , Antineoplásicos/uso terapêutico , Antígeno B7-H1/antagonistas & inibidores , Teorema de Bayes , Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/terapia , Quimioembolização Terapêutica/métodos , Terapia Combinada/métodos , Inibidores de Checkpoint Imunológico/uso terapêutico , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/terapia , Metanálise em Rede , Compostos de Fenilureia/uso terapêutico , Quinolinas/uso terapêutico , Resultado do TratamentoRESUMO
The Godoy Method of cervical lymphatic therapy is the first treatment option as monotherapy for children which facilitates achieving normalization or near normalization of the affected limb as well as the maintenance of the results, which could assist millions of children throughout the world.
Assuntos
Linfedema , Criança , Humanos , Linfedema/terapiaRESUMO
Background: Sporotrichosis is a zoonotic disease caused by a dimorphic fungi of the Sporothrix schenckii complex. It isan emerging zoonosis with worldwide distribution, thus of great importance to public health. The infection occurs fromtraumatic inoculation of the fungus in the human skin from contaminated plants and soils and through bites or scratchesof infected animals. The occurrence of sporotrichosis has been related to zoonotic transmission, especially by domesticfelines. This work aims to report the successful use of itraconazole as monotherapy in a case of localized feline sporotrichosis and highlight the effectiveness of cytology in its diagnosis.Case: A 1-year-and-4-month-old spayed female cat undefined breed, weighing 3.1 kg, was referred to the VeterinaryMedical Teaching Hospital of the Universidade Estadual de Maringá (UEM), city of Umuarama, presenting a serosanguinous ulcerative lesion located in the left periocular region The clinical picture of the patient progressed over 3 months.Treatments with antibiotic therapy, corticosteroids, and surgical procedures were conducted, without clinical improvement. A new lesion in the distal portion of the thoracic limb emerged, proving that the disease remained in progression.Hematological exams were performed, among them hemogram, renal and hepatic biochemical analyses, SNAPS to identifythe feline immunodeficiency virus feline leukemia virus (FIV/FeLV), and cytology of the lesion through imprints. Thehematological results were all within the normal standards for the species. Cytology showed a large amount of oval andfusiform structures phagocyted by polymorphonuclear cells, free at the bottom of the slide, compatible with Sporothrixspp. The treatment administered was itraconazole (100 mg/cat), orally administered every 24 h, cefovecin sodium 8 mg/kg,subcutaneous, single dose, topical use of...
Assuntos
Animais , Gatos , Esporotricose/terapia , Esporotricose/veterinária , Itraconazol/administração & dosagem , Itraconazol/uso terapêutico , Citodiagnóstico/veterinária , SporothrixRESUMO
Background: Sporotrichosis is a zoonotic disease caused by a dimorphic fungi of the Sporothrix schenckii complex. It isan emerging zoonosis with worldwide distribution, thus of great importance to public health. The infection occurs fromtraumatic inoculation of the fungus in the human skin from contaminated plants and soils and through bites or scratchesof infected animals. The occurrence of sporotrichosis has been related to zoonotic transmission, especially by domesticfelines. This work aims to report the successful use of itraconazole as monotherapy in a case of localized feline sporotrichosis and highlight the effectiveness of cytology in its diagnosis.Case: A 1-year-and-4-month-old spayed female cat undefined breed, weighing 3.1 kg, was referred to the VeterinaryMedical Teaching Hospital of the Universidade Estadual de Maringá (UEM), city of Umuarama, presenting a serosanguinous ulcerative lesion located in the left periocular region The clinical picture of the patient progressed over 3 months.Treatments with antibiotic therapy, corticosteroids, and surgical procedures were conducted, without clinical improvement. A new lesion in the distal portion of the thoracic limb emerged, proving that the disease remained in progression.Hematological exams were performed, among them hemogram, renal and hepatic biochemical analyses, SNAPS to identifythe feline immunodeficiency virus feline leukemia virus (FIV/FeLV), and cytology of the lesion through imprints. Thehematological results were all within the normal standards for the species. Cytology showed a large amount of oval andfusiform structures phagocyted by polymorphonuclear cells, free at the bottom of the slide, compatible with Sporothrixspp. The treatment administered was itraconazole (100 mg/cat), orally administered every 24 h, cefovecin sodium 8 mg/kg,subcutaneous, single dose, topical use of...(AU)
Assuntos
Animais , Gatos , Esporotricose/terapia , Esporotricose/veterinária , Itraconazol/administração & dosagem , Itraconazol/uso terapêutico , Sporothrix , Citodiagnóstico/veterináriaRESUMO
ABSTRACT Objective To determine under which health conditions metamizole (dipyrone) is used as a single drug or as fixed-dose combination. Methods Two retrospective cohorts of Brazilian patients treated with metamizole between January 2015 and December 2017 were analyzed: a metamizole-based cohort (Cohort 1) and a symptoms-based cohort (Cohort 2). Anonymized patient data was obtained from Amil Clinical Data Warehouse. The number of patients with symptoms was described by age and sex. Results The sample size of the two cohorts consisted of 384,668 patients. In patients using metamizole (Cohort 1), the most common reason for medication was the treatment of some form of pain (81%), followed by fever (19%). Headache was the most common (19%) specified pain class, followed by sore throat (8%), muscular pain (6%), and abdominal pain (5%). In adult patients (n=276,279; 71.8%), metamizole was used as a monotherapy or associated with another drug, for any sort of pain, in over 88% of the patients. General pain was the main reason for metamizole use in children (61%). Conclusion Real world evidence to evaluate Brazilian patients' therapeutic options is unusual and yet to be more explored using digital tools enabling better data registration. The present study confirmed that metamizole is widely used as a non-anti-inflammatory drug, and also showed the management of pain and fever as the most frequent indications in all age groups studied. Registry in Clinical Trials Database: REBEC Database: 10507
RESUMO
OBJECTIVE: Although it is known that methotrexate (MTX) increases the effectiveness of biological drugs (mainly anti-TNFs) in patients with rheumatoid arthritis (RA), in real life, it is known that many patients using anti-TNFs are on monotherapy due to many causes. This article compares the effectiveness of certolizumab as monotherapy as combined with MTX or leflunomide (LFN) in RA patients with failure to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in a real-world setting. METHODS: A retrospective observational cohort study was conducted at a specialized centre for RA management in Colombia. Patients treated with certolizumab as monotherapy or in combination with MTX, LFN, or MTX+LFN, between 2011 and 2020 with a minimum 3-month follow-up were included. Demographics and RA clinical characteristics were recorded; effectiveness was assessed as the improvement in Disease Activity Score (DAS28) getting remission or low disease activity at 3, 6, and 12 months of treatment. RESULTS: A total of 181 patients were included, 24 received certolizumab as monotherapy, 62 certolizumab plus MTX, 47 certolizumab plus LFN and 48 certolizumab plus MTX+LFN. At 3 months of follow-up, 80% of the patients showed decreased disease activity, with no significant differences between groups; at 12 months of treatment, response in certolizumab monotherapy group was 94.4% compared to 81.8% in combination with MTX, 80.5% in combination with LFN and 51.4% in combination with MTX+LFN. Response at 3 months (OR 4.04; 95% CI 1.28-12.69) and positive anti-CCP (OR 3.83; 95% CI 1.11-13.21) were associated with 12-month response. CONCLUSION: Certolizumab seems to be effective as monotherapy in the treatment of RA patients with failure to csDMARDs.
RESUMO
Introduction: Lymphedema is a specific type of edema that affects regions of the body in a chronic, progressive manner. Aim: The aim of the present study was to describe the therapeutic evolution of more than ten years of treatment for primary congenital lymphedema using the Godoy and Godoy method. Method: Ten children with primary congenital lymphedema with more than ten years of treatment at the Godoy Clinic were evaluated. Children with a clinical diagnosis of primary congenital lymphedema in treatment for more than 10 years with the Godoy Method. Cervical stimulation is the first treatment option of the method and is performed as monotherapy. The patients were reevaluated with weekly, bi-weekly and monthly frequencies and then every three months or when the family was able to return to the clinic. Results: For cases in which cervical stimulation was not possible, grosgrain stockings as monotherapy was the second therapeutic option. Conclusion: The Godoy and Godoy Method is effective at reducing edema in cases of primary congenital lymphedema, with the maintenance of the results throughout the treatment period.
RESUMO
Syringoma is a benign adnexal tumor of the skin originating from the eccrine sweat duct. There is a wide variety of treatments, and most of the patients receive multiple unsuccessful therapies. The goal of this report intends to describe a novel technique applicable to syringoma with botulinum toxin A. A 61-year-old female patient with localized syringomas in the periocular and upper lip region, with a long-lasting history, treated with botulinum toxin A 46 IU as monotherapy intradermally distributed and a follow-up for 8 months. Our patient displayed a significant improvement of the syringomas. Botulinum toxin A is an efficient and safe technique to treat syringomas.
Assuntos
Toxinas Botulínicas Tipo A , Neoplasias Cutâneas , Neoplasias das Glândulas Sudoríparas , Siringoma , Toxinas Botulínicas Tipo A/uso terapêutico , Feminino , Humanos , Pessoa de Meia-Idade , Pele , Neoplasias das Glândulas Sudoríparas/tratamento farmacológico , Siringoma/tratamento farmacológicoRESUMO
Introducción: El tratamiento con inhibidores de la fosfodiesterasa 5 a pacientes con cardiopatías adquiridas y congénitas, con hipertensión pulmonar, puede mejorar la calidad y pronóstico de vida, tanto en cardiopatías quirúrgicas como no quirúrgicas, con hipertensión pulmonar grave. Objetivos: Analizar los resultados de la monoterapia con sildenafilo en pacientes quirúrgicos y no quirúrgicos, con cardiopatías congénitas y adquiridas e hipertensión pulmonar grave. Método: Estudio descriptivo en 60 pacientes que recibieron sildenafilo para hipertensión arterial pulmonar grave, secundaria a cardiopatías adquiridas izquierdas, congénitas. Se observó: dosis, duración del tratamiento, tolerancia, evolución clínica y ecocardiográfica, clase funcional y tratamiento quirúrgico según resultados del cateterismo cardiaco. Resultados: En el período entre diciembre de 2017 a diciembre de 2018 se operaron con hipertensión arterial pulmonar grave, 20 enfermos con trastornos valvulares cardíacos izquierdos, 8 congénitos y 3 tumores cardíacos primarios, con administración de sildenafilo en dosis de 100 a 150 miligramos diarios. Hubo otros 29 pacientes con cardiopatías, que aunque no eran quirúrgicos, mejoraron su calidad y pronóstico de vida. Conclusiones: Resultó útil la indicación de sildenafilo, para mejorar la calidad y el pronóstico de vida, tanto en pacientes quirúrgicos como no quirúrgicos con cardiopatías e hipertensión pulmonar grave(AU)
Introduction: Treatment with phosphodiesterase 5 inhibitors in patients with acquired and congenital heart disease, with pulmonary hypertension, can improve the quality and prognosis of life, both in surgical and non-surgical heart disease, with severe pulmonary hypertension. Objectives: To analyze the results of sildenafil monotherapy in surgical and non-surgical patients, with congenital and acquired heart disease and severe pulmonary hypertension. Method: Descriptive study in 60 patients who received sildenafil for severe pulmonary arterial hypertension, secondary to congenital left acquired heart disease. It was observed: dose, duration of treatment, tolerance, clinical and echocardiographic evolution, functional class and surgical treatment according to cardiac catheterization results. Results: In the period between December 2017 and December 2018, 20 patients with left heart valvular disorders, 8 congenital and 3 primary cardiac tumors, with sildenafil daily administration doses of 100 to 150 milligrams, were operated with severe pulmonary arterial hypertension. There were 29 other patients with heart disease, which although they were not surgical, improved their quality and prognosis of life. Conclusions: The prescription of sildenafil was useful to improve the quality and prognosis of life, both in surgical and non-surgical patients with heart disease and severe pulmonary hypertension(AU)
Assuntos
Humanos , Masculino , Feminino , Organização e Administração , Dosagem , Hipertensão Arterial Pulmonar , Cardiopatias Congênitas , Hipertensão Pulmonar , Estudos Transversais , Estudo ObservacionalRESUMO
RESUMEN Se presenta la segunda parte de las recomendaciones latinoamericanas para el manejo de la Hipertensión Arterial (HTA) en adultos. En una primera fase se han descripto los aspectos más relevantes de la epidemiología, aspectos fisiopatológicos, cómo hacer diagnóstico, pautas terapéuticas, urgencias y emergencias hipertensivas, poblaciones especiales, hipertensión refractaria y la aplicación de las guías en la vida real. En esta segunda parte, se emiten recomendaciones respondiendo a preguntas específicas para prevención primaria, secundaria, terciaria y cuaternaria. En general pocas recomendaciones al respecto del manejo de la hipertensión arterial surgen desde la clínica médica/ medicina interna, a pesar de dos situaciones: la mayoría de los pacientes con hipertensión arterial son evaluados y manejados por los clínicos, y la clínica médica es la especialidad que permite la mirada holística e integrada de los problemas de salud del adulto, permitiendo agregar el enfoque biográfico al biológico, comprender e interpretar no solo el problema de salud sino sus causas y consecuencias (que muchas veces suelen corresponder a diferentes parénquimas, lo cual en el modelo fragmentado haría transitar al paciente por distintas especialidades). El bajo porcentaje de pacientes hipertensos controlados obliga a todos los profesionales involucrados en el manejo de los mismos a optimizar recursos y detectar problemas que se asocien a un control deficitario como la sub utilización del tratamiento farmacológico, baja tasa de pacientes tratados con estrategia combinada (la mayoría de los pacientes actualmente recibe monoterapia), falta de prescripción adecuada de los cambios en el estilo de vida, baja adherencia terapéutica e inercia clínica. En la presente publicación se presentan recomendaciones efectuadas por especialistas en clínica médica / medicina interna para el manejo de la hipertensión arterial en adultos, respondiendo preguntas de prevención primaria, secundaria, terciaria, y cuaternaria.
ABSTRACT The second part of the Latin American recommendations for the management of Arterial Hypertension (HTA) in adults is presented. In a first phase, the most relevant aspects of epidemiology, physiopathological aspects, how to diagnose, therapeutic guidelines, hypertension emergencies, special populations, refractory hypertension and the application of guides in real life have been described. In this second part, recommendations are issued answering specific questions for primary, secondary, tertiary and quaternary prevention. In general, few recommendations regarding the management of arterial hypertension arise from the medical clinic / internal medicine, despite two situations: the majority of patients with hypertension are evaluated and managed by the clinicians, and the medical clinic is the specialty that allows the holistic and integrated look of the health problems in adults, allowing to add the biographical approach to the biological, to understand and interpret not only the health problem but its causes and consequences (which often correspond to different parenchyma, which in the fragmented model would make the patient move through different specialties). The low percentage of controlled hypertensive patients forces all the professionals involved in the management of them to optimize resources and detect problems that are associated with a deficit control such as the under utilization of pharmacological treatment, low rate of patients treated with combined strategy (the most patients currently receive monotherapy), lack of adequate prescription of changes in lifestyle, low therapeutic adherence and clinical inertia. This publication presents recommendations made by specialists in medical clinic/internal medicine for the management of hypertension in adults, answering primary, secondary, tertiary and quaternary prevention questions.
RESUMO
OBJECTIVE: To evaluate the efficacy and safety of valsartan (V) or chlorthalidone (C) monotherapy in comparison with a fixed combination of valsartan and chlorthalidone (V + C). METHODS: This 12-week multicenter randomized three-arm open-label study randomly allocated 72 patients to V or C as monotherapy or a combination of V + C. The aim was to measure changes in office systolic blood pressure (SBP) and diastolic blood pressure (DBP) and in 24-hour ambulatory blood pressure monitoring (ABPM) from baseline to week 12, in addition to medication tolerability. RESULTS: The proportion of patients achieving target BP in office at week 12 was not statistically different for the three groups. However, comparisons of daytime and nighttime 24-hour ABPM values from baseline to week 12 revealed significant differences in nighttime mean SBP for the three groups, due to a significantly greater reduction in the values in patients assigned to the V + C group (-14.7 vs. -8.7 vs. -10.7, P = .042, V+C; V; C, respectively). Although patients assigned to the V + C group also had greater nighttime reduction in mean DBP values compared with those in the other groups, this difference was not statistically significant. The incidence of adverse events did not differ significantly. CONCLUSION: In patients with hypertension treated with V, C, and both medications combined, the fixed combination of V + C provided a significantly greater reduction of late night to early morning BP values when interventions were assessed with 24-hour ABPM. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT.01850160, https://clinicaltrials.gov/ct2/show/NCT01850160.
RESUMO
Onychomycosis is an infection of the nail plate by fungal microorganisms. This infection has an important social impact on women and men and poses a major challenge for its treatment. The traditional treatment of onychomycosis involves the use of topical and oral antifungal agents. However, the presence of adverse effects frequently associated with oral antifungals, their high cost, and their potential interactions with other drugs reflect some of the problems associated with conventional therapy. The current report details the evaluation of a 1340nm laser as monotherapy for toenails affected by onychomycosis. A 1340nm, neodymium-yttrium:yttrium-aluminum-perovskite (Nd:YAP) (e) laser (Etherea, Industra technologies, Brazil) was used with the following treatment parameters: a spot size of 6mm, pulse duration of 5ms, fluence of 22 to 25J/cm2, and repetition rate of 1.5 to 2.5Hz. In all, 72 toenails were evaluated in 30 patients who had clinical and laboratory confirmation of onychomycosis. The efficacy of treatment was measured by the degree of patient satisfaction on a scale of 0 to 10 and by mycological cure evidenced by direct mycological exam and culture. Considering three applications of laser therapy and a clinical/laboratory follow-up period of 12 weeks, monotherapy with 1340nm laser was not effective, since 93.3 percent of the assessed patients remained without clinical and mycological cure. Despite reports of variable success rates with the use of different lasers for the treatment of onychomycosis, it is not yet possible to state that this therapeutic alternative is indicated for the treatment of these infections, mainly due to the limited number of patients and/or nail plates evaluated and the controversial results described in the literature.
RESUMO
Las guías clínicas recomiendan la monoterapia antipsicótica (mta). La polifarmacia antipsicótica (pfa, uso concomitante de dos o más antipsicóticos) es una práctica clínica frecuente. El objetivo del trabajo fue determinar el perfil de prescripción antipsicótica y su uso en mta o pfa, al egreso hospitalario durante el período abril setiembre de 2012 en el Hospital Vilardebó. Se realizó un estudio descriptivo, observacional y retrospectivo. Las variables estudiadas fueron sexo, edad, medicación y diagnóstico. Se definió mta para los que egresaron con un antipsicótico y pfa para aquellos que egresaron con dos o más antipsicóticos. El 52 % egresó con mta, de los cuales el 42% recibió un antipsicótico atípico y el 10%, uno típico. El 48 % restante egresó con dos o más antipsicóticos (pfa). El 19 % de los pacientes con pfa egresó con tres o más antipsicóticos. Es elevado el uso de pfa al egreso hospitalario.
Assuntos
Humanos , Masculino , Feminino , Alta do Paciente , Antipsicóticos/administração & dosagem , Prescrições de Medicamentos , Polimedicação , UruguaiRESUMO
Las guías clínicas recomiendan la monoterapia antipsicótica (mta). La polifarmacia antipsicótica (pfa, uso concomitante de dos o más antipsicóticos) es una práctica clínica frecuente. El objetivo del trabajo fue determinar el perfil de prescripción antipsicótica y su uso en mta o pfa, al egreso hospitalario durante el período abril setiembre de 2012 en el Hospital Vilardebó. Se realizó un estudio descriptivo, observacional y retrospectivo. Las variables estudiadas fueron sexo, edad, medicación y diagnóstico. Se definió mta para los que egresaron con un antipsicótico y pfa para aquellos que egresaron con dos o más antipsicóticos. El 52 % egresó con mta, de los cuales el 42% recibió un antipsicótico atípico y el 10%, uno típico. El 48 % restante egresó con dos o más antipsicóticos (pfa). El 19 % de los pacientes con pfa egresó con tres o más antipsicóticos. Es elevado el uso de pfa al egreso hospitalario.
Assuntos
Humanos , Masculino , Feminino , Antipsicóticos/administração & dosagem , Prescrições de Medicamentos , Alta do Paciente , Polimedicação , UruguaiRESUMO
PURPOSE: High-dose-rate (HDR) brachytherapy has been accepted as an effective and safe method to treat prostate cancer. The aim of this study was to describe acute toxicity following HDR brachytherapy to the prostate, and to examine the association between dosimetric parameters and urinary toxicity in low-risk prostate cancer patients. MATERIAL AND METHODS: Patients with low-risk prostate cancer were given HDR brachytherapy as monotherapy in two 12.5 Gy fractions. Planning objectives for the planning target volume (PTV) were V100% ≥ 90% and V150% ≤ 35%. Planning objectives for organs at risk were V75% ≤ 1 cc for the bladder, rectum and perineum, and V125% ≤ 1 cc for the urethra. Toxicity was assessed three months after treatment using the Common Terminology Criteria for Adverse Events. RESULTS: Seventy-three patients were included in the analysis. Thirty-three patients (45%) reported having any type of toxicity in the three months following HDR brachytherapy. Most toxicity cases (26%) were grade 1 urinary toxicity. Mean coverage index was 0.89 and mean V100 was 88.85. Doses administered to the urethra were associated with urinary toxicity. Patients who received more than 111.3% of the prescribed dose in 1 cc of the urethra were four times more likely to have urinary toxicity compared to patients receiving less than 111.3% (OR = 4.71, 95% CI: 1.43-15.6; p = 0.011). CONCLUSIONS: High-dose-rate brachytherapy administered as monotherapy for prostate cancer proved to be a safe alternative treatment for patients with low-risk prostate cancer. Urinary toxicity was associated with the dose administered to 1 cc and 0.1 cc of the urethra and was remarkably inferior to the reported toxicity in similar studies.
RESUMO
BACKGROUND: Androgenetic alopecia (AGA) is the most common form of hair loss in men and in women. Currently, minoxidil and finasteride are the treatments with the highest levels of medical evidence, but patients who exhibit intolerance or poor response to these treatments are in need of additional treatment modalities. OBJECTIVE: The aim was to evaluate the efficacy and safety of low-level laser therapy (LLLT) for AGA, either as monotherapy or as concomitant therapy with minoxidil or finasteride, in an office-based setting. MATERIALS AND METHODS: Retrospective observational study of male and female patients with AGA, treated with the 655 nm-HairMax Laser Comb(®), in an office-based setting. Efficacy was assessed with global photographic imaging. RESULTS: Of 32 patients (21 female, 11 male), 8 showed significant, 20 moderate, and 4 no improvement. Improvement was seen both with monotherapy and with concomitant therapy. Improvement was observed as early as 3 months and was sustained up to a maximum observation time of 24 months. No adverse reactions were reported. CONCLUSIONS: LLLT represents a potentially effective treatment for both male and female AGA, either as monotherapy or concomitant therapy. Combination treatments with minoxidil, finasteride, and LLLT may act synergistic to enhance hair growth.
RESUMO
Assuntos
Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Adesão à Medicação/estatística & dados numéricos , Transtornos de Enxaqueca/tratamento farmacológico , Medicamentos sob Prescrição/uso terapêutico , Antagonistas de Receptores Adrenérgicos beta 1/uso terapêutico , Antidepressivos/uso terapêutico , Brasil , Quimioterapia Combinada/métodos , Flunarizina/uso terapêutico , Relaxantes Musculares Centrais/uso terapêutico , Estudos Retrospectivos , Fatores de Tempo , Resultado do TratamentoRESUMO
En este trabajo se revisa la información actual sobre el uso de los nuevos fármacos antiepilépticos (FAEs) en monoterapia en niños, resaltando nuestra experiencia personal. Específicamente, se incluyen los siguientes FAEs: lamotrigina (Lamictal®), topiramato (Topamax®), zonisamida (Zonegran®), levetiracetam (Keppra®), y oxcarbacepina (Trileptal®). Todos estos FAEs tienen un amplio espectro de acción en el tratamiento de crisis epilépticas parciales y generalizadas, excepto la oxcarbacepina, que es eficaz exclusivamente en crisis parciales. No está claro si la monoterapia con estos FAEs, en comparación con los FAEs clásicos (fenobarbital, fenitoína, carbamacepina, valproato sódico), proporciona una mayor eficacia y/o causa menos efectos secundarios y, si por lo tanto, mejora significativamente la calidad de vida de los niños con epilepsia. Se necesitan más estudios para poder contestar estas preguntas.
In this paper we review the current information regarding the use of new antiepileptic drugs (AEDs) used as monotherapy in children. We specifically include the following AEDs: lamotrigine (Lamictal®), topiramate (Topamax®), zonisamide (Zonegran®), levetiracetam (Keppra®), and oxcarbazepine (Trileptal®). All of these AEDs have a broad spectrum of action in the treatment of partial and generalized seizures, except Oxcarbazepine, which is effective only in partial seizures. It is unclear whether or not monotherapy with the new AEDs offers higher efficacy and/or lower side effects compared to classic AEDs (phenobarbital, phenytoin, carbamazepine, or valproate) thereby significantly improving the quality of life in children with epilepsy. More studies are needed to answer these questions.